

Seagen and Genmab – U.S. Call For Grant Applications
(CGA Advanced Cervical Cancer 2101)

Independent Medical Education

Therapeutic Area: Oncology
Disease State: Advanced Cervical Cancer
CGA Name: Advanced CC 2101
Release Date: Nov 5th, 2021

Eligibility Requirements

General	U.S. based provider that is accredited to provide CME/CE and in good standing, e.g. ACCME, ANCC, ACPE, etc.
Geographical Scope	United States (and OUS on demand only)
Grant Submission Timeframe:	Nov. 8th - Dec. 8th, 2021
Specific Area of Interest	<p>The purpose of this <i>Call for Grant Application</i> (CGA) is to encourage organizations to submit grant applications for independent education designed to enhance understanding of increasingly complex treatment landscape options and close educational gaps in advanced cervical cancer (advanced CC). Activity design may be live, enduring or multi-format, including but not limited to, satellite symposia at annual professional conferences, tweetorials, podcasts or meeting series. Knowledge gaps in advanced CC which have been identified in the public healthcare landscape and are inclusive of the following:</p> <ul style="list-style-type: none">• Mechanism of action and management of side effects associated with administration of novel treatment options used to treat recurrent/metastatic CC.• How emerging data for recurrent or metastatic CC shape the future treatment landscape.
Monetary Range:	Individual requests up to \$150,000.00, for full or partial funding of programs, will be considered. Multi-supported educational activities are preferred. The amount of any grant funding may vary from the amount requested.
Target Audience:	Comprehensive Care Team in community or academic settings including, Oncology Infusion Nurses, NPs/PAs and/or other associated care team members, e.g. ophthalmologists, endocrinologists, who manage the treatment of patients with advanced CC.
Target Performance Timeframe:	ASAP – Oct 2022

Purpose

Seagen, and its partner in fighting cervical cancer, Genmab, are committed to supporting innovative, high quality, independent medical education (IME) for healthcare professionals that addresses unmet medical educational needs, fosters clinical excellence, and improves health outcomes in our therapeutic areas of interest.

The intent of this CGA is to encourage organizations to submit grant requests for IME activities that, if funded, will address the following educational needs and practice gaps for the comprehensive healthcare team, including but not limited to:

- How newly approved and emerging therapy options in r/mCC can be sequenced to produce optimal health outcomes for patients
- Effectively identifying and managing side effects of novel therapies used to treat r/mCC
- Identifying the different roles of the comprehensive care team in providing optimal care for patients with r/mCC, e.g. nurses, pharmacists, endocrinologists and ophthalmologists

When responding to this CGA, please adhere to the following principles in addition to the established guidelines for the Seagen IME grant application process. All applications must be submitted online through the Seagen Grant Management System, accessible at <https://www.seagen.com/healthcare-professionals/medical-education> . Seagen will review all submissions in response to, and in compliance with, this CGA.

Background

Given the rapid increase in number of therapies and emerging data for r/mCC patients, it is important to understand how to optimize treatment plan for r/mCC patients. Awareness of treatment-related AEs (TRAEs), appropriate patient counseling, and management of symptoms cannot only enable safe and effective use of these novel treatment options, but also have a significant impact on patient quality of life (Davidson, 2011). Therefore, it is critical that the comprehensive care team understand their role in monitoring and managing AEs associated with r/mCC treatment options and for optimal patient outcomes.

Outcomes Measures

Applications should include a detailed plan to provide quantitative evidence to show that the educational initiative had impact on healthcare provider knowledge, competence, and/or performance outcomes (Moore’s outcome level 3 - 5). Ideally, the evaluation plan will include quantitative and qualitative evidence that the intervention(s) has had an impact on health care professional behavior. Additionally, we request reports be provided for interim and final outcomes and the impact of the project.

Additional Eligibility Requirements

The IME must be accredited and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the IME must be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration’s Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

Grant Submission Instructions:

Submission Instructions	Application Process	Deadlines
Step 1	Organizations who meet the eligibility criteria and are interested in submitting a full grant application in response to this CGA may do so at https://www.seagen.com/healthcare-professionals/medical-education and select “grant management system” button. Organizations are asked to title the start of their grant with “ CGA 2101 : [include your grant title]”	December 8, 2021
Step 2	Anticipated notification of decisions via email will occur*	Mid-Dec 2021 through Jan 14, 2022.

Questions	If you have any questions regarding this Call for Grants, please direct them in writing to Grant Administrator at grants@seagen.com , with the subject line “CGA 2101”.
-----------	--

* There have been no pre-determined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.

Other submission Information:

- Grants will not be provided to individuals.
- Seagen adheres to the guidelines of the Accreditation Council for Continuing Medical Education (ACCME) and FDA Guidance for Industry-Supported Scientific and Educational Activities and does not influence or control the content of any IME it supports.
- Seagen will consider providing funding only for IME that is balanced and scientifically rigorous.
- Grants are supported by Seagen and its collaboration partner Genmab. Accordingly, Seagen requests that any grant recipients acknowledge the support of both Seagen and Genmab.
- Any type of funding provided by Seagen and Genmab may not be tied in any way to the use, purchase, prescription or recommendation of any current or future Seagen or Genmab product.

Terms and Conditions:

1. All grant applications received in response to this CGA will be reviewed by Seagen in accordance with its policies and guidelines.
2. This CGA does not commit Seagen or Genmab to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Seagen reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGA.
4. All communications about the CGA must be sent to Seagen IME at grants@seagen.com. For compliance reasons, and in fairness to all providers, all communications about this CGA must come exclusively to Seagen’s department of Medical Education. Failure to comply will automatically disqualify providers.
5. Applicant and/or educational partner (if applicable) shall have complete control over the content, development and implementation of the IME and/or materials, including, if applicable, the selection of faculty.
6. Failure to follow instructions within this CGA may result in a denial of the grant application.

Transparency: Seagen and Genmab, in their sole discretion, have the right to disclose the details of funded independent medical education activities, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Seagen website.